AU2017314178B2 - Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof - Google Patents

Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof Download PDF

Info

Publication number
AU2017314178B2
AU2017314178B2 AU2017314178A AU2017314178A AU2017314178B2 AU 2017314178 B2 AU2017314178 B2 AU 2017314178B2 AU 2017314178 A AU2017314178 A AU 2017314178A AU 2017314178 A AU2017314178 A AU 2017314178A AU 2017314178 B2 AU2017314178 B2 AU 2017314178B2
Authority
AU
Australia
Prior art keywords
crystalline form
solid
lymphoma
compound
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017314178A
Other languages
English (en)
Other versions
AU2017314178A1 (en
Inventor
Yunhang GUO
Gongyin SHI
Zhiwei Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beone Medicines I GmbH
Original Assignee
Beone Medicines I GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61197220&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2017314178(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Beone Medicines I GmbH filed Critical Beone Medicines I GmbH
Publication of AU2017314178A1 publication Critical patent/AU2017314178A1/en
Application granted granted Critical
Publication of AU2017314178B2 publication Critical patent/AU2017314178B2/en
Priority to AU2022200278A priority Critical patent/AU2022200278B2/en
Assigned to BEIGENE SWITZERLAND GMBH reassignment BEIGENE SWITZERLAND GMBH Request for Assignment Assignors: BEIGENE, LTD.
Priority to AU2024200030A priority patent/AU2024200030A1/en
Assigned to BEONE MEDICINES I GMBH reassignment BEONE MEDICINES I GMBH Request to Amend Deed and Register Assignors: BEIGENE SWITZERLAND GMBH
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2017314178A 2016-08-16 2017-08-15 Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof Active AU2017314178B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2022200278A AU2022200278B2 (en) 2016-08-16 2022-01-17 Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hy dropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
AU2024200030A AU2024200030A1 (en) 2016-08-16 2024-01-03 Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2016/095510 2016-08-16
CN2016095510 2016-08-16
PCT/IB2017/054955 WO2018033853A2 (en) 2016-08-16 2017-08-15 Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2022200278A Division AU2022200278B2 (en) 2016-08-16 2022-01-17 Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hy dropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof

Publications (2)

Publication Number Publication Date
AU2017314178A1 AU2017314178A1 (en) 2019-04-04
AU2017314178B2 true AU2017314178B2 (en) 2021-11-18

Family

ID=61197220

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2017314178A Active AU2017314178B2 (en) 2016-08-16 2017-08-15 Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
AU2022200278A Active AU2022200278B2 (en) 2016-08-16 2022-01-17 Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hy dropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
AU2024200030A Pending AU2024200030A1 (en) 2016-08-16 2024-01-03 Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2022200278A Active AU2022200278B2 (en) 2016-08-16 2022-01-17 Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hy dropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
AU2024200030A Pending AU2024200030A1 (en) 2016-08-16 2024-01-03 Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof

Country Status (15)

Country Link
US (12) US10927117B2 (enExample)
EP (3) EP3500575B1 (enExample)
JP (4) JP7402685B2 (enExample)
KR (3) KR102793825B1 (enExample)
CN (3) CN116478165A (enExample)
AU (3) AU2017314178B2 (enExample)
CA (1) CA3033827A1 (enExample)
EA (1) EA201990519A1 (enExample)
IL (2) IL293319A (enExample)
MX (1) MX384627B (enExample)
NZ (1) NZ751418A (enExample)
SG (1) SG11201901141WA (enExample)
TW (3) TWI884890B (enExample)
WO (1) WO2018033853A2 (enExample)
ZA (1) ZA201900919B (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015025260B1 (pt) 2013-04-25 2021-11-03 Beigene, Ltd Compostos heterocíclicos fundidos como inibidores da proteína quinase, sua composição, combinação e uso
ES2927567T3 (es) 2013-09-13 2022-11-08 Beigene Switzerland Gmbh Anticuerpos anti-PD1 y su uso como productos terapéuticos y de diagnóstico
CN110156892B (zh) 2014-07-03 2023-05-16 百济神州有限公司 抗pd-l1抗体及其作为治疗剂及诊断剂的用途
CN109475536B (zh) 2016-07-05 2022-05-27 百济神州有限公司 用于治疗癌症的PD-l拮抗剂和RAF抑制剂的组合
SG11201901141WA (en) 2016-08-16 2019-03-28 Beigene Ltd Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
CA3034326A1 (en) 2016-08-19 2018-02-22 Beigene, Ltd. Use of a combination comprising a btk inhibitor for treating cancers
WO2018137681A1 (en) 2017-01-25 2018-08-02 Beigene, Ltd. Crystalline forms of (s) -7- (1- (but-2-ynoyl) piperidin-4-yl) -2- (4-phenoxyphenyl) -4, 5, 6, 7-tetrahy dropyrazolo [1, 5-a] pyrimidine-3-carboxamide, preparation, and uses thereof
KR102757960B1 (ko) 2017-06-26 2025-01-22 베이진 엘티디 간세포암(hepatocellular carcinoma: HCC)에 대한 면역 치료
US11377449B2 (en) 2017-08-12 2022-07-05 Beigene, Ltd. BTK inhibitors with improved dual selectivity
WO2019108795A1 (en) 2017-11-29 2019-06-06 Beigene Switzerland Gmbh Treatment of indolent or aggressive b-cell lymphomas using a combination comprising btk inhibitors
EP3773330B1 (en) * 2018-03-29 2025-03-05 Mati Therapeutics Inc. Ophthalmic drug sustained release formulation and uses for dry eye syndrome treatment
CN111675711A (zh) * 2019-03-11 2020-09-18 百济神州(苏州)生物科技有限公司 Btk抑制剂化合物的单晶及其制备方法
CN111909152B (zh) * 2019-05-08 2023-12-15 百济神州(苏州)生物科技有限公司 Btk抑制剂及其中间体的制备方法
JP2022534650A (ja) 2019-05-31 2022-08-03 海思科医▲薬▼有限公司 Ｂｔｋ阻害薬環誘導体、その調製方法及びその医薬品適用
CN112057427B (zh) * 2019-06-10 2024-09-03 百济神州(苏州)生物科技有限公司 一种含有布鲁顿氏酪氨酸激酶抑制剂的口服固体片剂及其制备方法
CN112057432A (zh) * 2019-06-10 2020-12-11 百济神州(苏州)生物科技有限公司 口服胶囊剂及其制备方法
TWI856111B (zh) * 2019-06-10 2024-09-21 瑞士商百濟神州瑞士有限責任公司 一種含有布魯頓氏酪胺酸激酶抑制劑的口服固體錠劑及其製備方法
JP2022538215A (ja) * 2019-06-10 2022-09-01 ベイジーン スウィッツァーランド ゲーエムベーハー 経口カプセルおよびその調製方法
CN110563733A (zh) * 2019-09-12 2019-12-13 安帝康（无锡）生物科技有限公司 作为选择性btk抑制剂的咪唑并吡嗪类化合物
CN114761399B (zh) * 2019-12-04 2024-03-26 河南知微生物医药有限公司 作为布鲁顿酪氨酸激酶抑制剂的咪唑甲酰胺衍生物
CN110845504A (zh) * 2019-12-19 2020-02-28 武汉九州钰民医药科技有限公司 合成赞布替尼的新方法
CN110922409A (zh) * 2019-12-19 2020-03-27 武汉九州钰民医药科技有限公司 制备btk抑制剂泽布替尼的方法
CN110938077B (zh) * 2019-12-25 2021-04-27 武汉九州钰民医药科技有限公司 合成Avapritinib的方法
US20230089557A1 (en) * 2020-02-27 2023-03-23 Beigene Switzerland Gmbh Methods of treating dlbcl using btk inhibitors and combinations thereof
WO2021259732A1 (en) 2020-06-24 2021-12-30 Sandoz Ag Multi-component compounds comprising zanubrutinib and a benzoic acid derivative
CN116134028A (zh) 2020-07-07 2023-05-16 四川海思科制药有限公司 一种具有降解btk激酶的化合物及其制备方法和药学上的应用
WO2022101939A1 (en) * 2020-11-13 2022-05-19 Msn Laboratories Private Limited, R&D Center Novel process for the preparation of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide or its salts thereof
KR20230107866A (ko) * 2020-11-20 2023-07-18 베이진 스위찰랜드 게엠베하 Btk 억제제를 사용한 전신성 홍반성 루푸스의 치료 방법
EP4259633A1 (en) 2020-12-11 2023-10-18 Teva Pharmaceuticals International GmbH Processes for the preparation of zanubrutinib and intermediates thereof
WO2022140246A1 (en) 2020-12-21 2022-06-30 Hangzhou Jijing Pharmaceutical Technology Limited Methods and compounds for targeted autophagy
WO2023014817A1 (en) 2021-08-03 2023-02-09 Syros Pharmaceuticals, Inc. Compositions and methods for treating lymphomas with a cdk7 inhibitor in combination with a btk inhibitor
IT202100025997A1 (it) 2021-10-11 2023-04-11 Olon Spa Processo per la preparazione di zanubrutinib
IT202200009872A1 (it) * 2022-05-12 2023-11-12 Olon Spa Processo di preparazione di Zanubrutinib in forma amorfa.
IT202200024192A1 (it) * 2022-11-24 2024-05-24 Olon Spa Processo per la preparazione di Zanubrutinib.
CN118307541A (zh) * 2023-01-09 2024-07-09 天津济坤医药科技有限公司 氘代吡唑并嘧啶衍生物及其制备方法和药物组合物、结合物及应用
CN117430610A (zh) * 2023-10-11 2024-01-23 宁夏医科大学 一种氘代稠合杂环化合物及其制备方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014173289A1 (en) * 2013-04-25 2014-10-30 Beigene, Ltd. Fused heterocyclic compounds as protein kinase inhibitors

Family Cites Families (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE792533A (fr) 1971-12-09 1973-06-08 Int Chem & Nuclear Corp Nouvelles pyrazolo (1,5a) pyrimidines et leur procede de preparation
JP2778921B2 (ja) 1994-11-18 1998-07-23 三共株式会社 イミダゾピラゾール誘導体
DK1206474T3 (da) 1999-08-27 2004-10-04 Abbott Lab Sulfonylphenylpyrazolforbindelser anvendelige som cox-2-inhibitorer
EP1212327B8 (en) * 1999-09-17 2004-02-25 Abbott GmbH & Co. KG Pyrazolopyrimidines as therapeutic agents
WO2002020740A2 (en) 2000-09-08 2002-03-14 California Institute Of Technology Proteolysis targeting chimeric pharmaceutical
US20020094989A1 (en) * 2000-10-11 2002-07-18 Hale Jeffrey J. Pyrrolidine modulators of CCR5 chemokine receptor activity
AU2002223968A1 (en) * 2000-12-21 2002-07-01 Warner Lambert Company Llc Piperidine derivatives as subtype selective n-methyl-d-aspartate antagonists
DK1347971T3 (da) 2000-12-21 2006-05-15 Bristol Myers Squibb Co Thiazolylinhibitorer af tyrosinkinaser fra Tec-familien
ATE309997T1 (de) 2001-03-09 2005-12-15 Pfizer Prod Inc Entzündungshemmende benzimidazolverbindungen
WO2003004497A1 (en) 2001-07-05 2003-01-16 Sumitomo Pharmaceuticals Company, Limited Novel heterocyclic compound
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7514441B2 (en) 2002-08-26 2009-04-07 Takeda Pharmaceutical Company Limited Substituted pyrazolo [1,5-A]pyrimidines as calcium receptor modulating agents
ZA200500782B (en) 2002-08-26 2007-10-31 Takeda Pharmaceutical Calcium receptor modulating compound and use thereof
US7405295B2 (en) 2003-06-04 2008-07-29 Cgi Pharmaceuticals, Inc. Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds
US20060183746A1 (en) 2003-06-04 2006-08-17 Currie Kevin S Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds
US7393848B2 (en) 2003-06-30 2008-07-01 Cgi Pharmaceuticals, Inc. Certain heterocyclic substituted imidazo[1,2-A]pyrazin-8-ylamines and methods of inhibition of Bruton's tyrosine kinase by such compounds
AU2004260689B8 (en) 2003-07-29 2008-05-15 Irm Llc Compounds and compositions as protein kinase inhibitors
WO2005047290A2 (en) 2003-11-11 2005-05-26 Cellular Genomics Inc. Imidazo[1,2-a] pyrazin-8-ylamines as kinase inhibitors
SG159549A1 (en) 2004-11-10 2010-03-30 Cgi Pharmaceuticals Inc Imidazo[1,2-a] pyrazin-8-ylamines useful as modulators of kinase activity
RU2423351C2 (ru) 2004-12-16 2011-07-10 Вертекс Фармасьютикалз Инкорпорейтед Пирид-2-оны, применимые как ингибиторы протеинкиназ семейства тес для лечения воспалительных, пролиферативных и иммунологически-опосредованных заболеваний
AU2006223409B2 (en) 2005-03-10 2011-07-21 Gilead Connecticut, Inc. Certain substituted amides, method of making, and method of use thereof
ATE528302T1 (de) 2005-08-29 2011-10-15 Vertex Pharma 3,5-disubstituierte pyrid-2-one, die als hemmer der tec-familie von nicht-rezeptor tyrosin- kinasen nützlich sind
US7691885B2 (en) 2005-08-29 2010-04-06 Vertex Pharmaceuticals Incorporated Pyridones useful as inhibitors of kinases
WO2007026720A1 (ja) * 2005-08-31 2007-03-08 Taisho Pharmaceutical Co., Ltd. 縮環ピラゾール誘導体
JP5066516B2 (ja) 2005-09-01 2012-11-07 アステラス製薬株式会社 疼痛の治療に用いられるピリダジノン誘導体
MX2008008642A (es) 2006-01-13 2008-09-12 Pharmacyclics Inc Inhibidores de las tirosina cinasas y usos de los mismos.
CA2651732C (en) 2006-05-18 2014-10-14 Mannkind Corporation Intracellular kinase inhibitors
TWI398252B (zh) 2006-05-26 2013-06-11 Novartis Ag 吡咯并嘧啶化合物及其用途
PE20080839A1 (es) 2006-09-11 2008-08-23 Cgi Pharmaceuticals Inc Determinadas amidas sustituidas, metodo de elaboracion y metodo de uso de las mismas
AR063946A1 (es) 2006-09-11 2009-03-04 Cgi Pharmaceuticals Inc Determinadas pirimidinas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden.
PE20081370A1 (es) 2006-09-11 2008-11-28 Cgi Pharmaceuticals Inc Determinadas amidas sustituidas, metodo de elaboracion y metodo de uso de las mismas
JP2010502751A (ja) 2006-09-11 2010-01-28 シージーアイ ファーマシューティカルズ，インコーポレイティド キナーゼ阻害物質、およびキナーゼ阻害物質の使用および同定方法
SI2529622T1 (en) 2006-09-22 2018-06-29 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
WO2008045627A2 (en) 2006-10-06 2008-04-17 Irm Llc Protein kinase inhibitors and methods for using thereof
WO2008054827A2 (en) 2006-11-03 2008-05-08 Pharmacyclics, Inc. Bruton's tyrosine kinase activity probe and method of using
EP2125819B1 (en) 2007-03-21 2014-10-22 Bristol-Myers Squibb Company Fused heterocyclic compounds useful for the treatment of proliferative, allergic, autoimmune or inflammatory diseases
WO2008144253A1 (en) 2007-05-14 2008-11-27 Irm Llc Protein kinase inhibitors and methods for using thereof
CL2008002793A1 (es) 2007-09-20 2009-09-04 Cgi Pharmaceuticals Inc Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras
TWI552752B (zh) 2007-10-19 2016-10-11 賽基艾維洛米斯研究股份有限公司 雜芳基化合物及其用途
US7989465B2 (en) 2007-10-19 2011-08-02 Avila Therapeutics, Inc. 4,6-disubstituted pyrimidines useful as kinase inhibitors
EP2426109B1 (en) 2007-10-23 2013-12-18 F. Hoffmann-La Roche AG Novel kinase inhibitors
JP5643105B2 (ja) 2007-12-14 2014-12-17 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 新規イミダゾ［１，２−ａ］ピリジン及びイミダゾ［１，２−ｂ］ピリダジン誘導体
EP2242749B1 (en) 2008-02-05 2013-04-10 F. Hoffmann-La Roche AG Novel pyridinones and pyridazinones
ES2554615T3 (es) 2008-05-06 2015-12-22 Gilead Connecticut, Inc. Amidas sustituidas, método de preparación y utilización como inhibidores de Btk
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
TWI546290B (zh) 2008-06-27 2016-08-21 賽基艾維洛米斯研究股份有限公司 雜芳基化合物及其用途
CA2728683C (en) 2008-07-02 2017-05-02 F.Hoffmann-La Roche Ag Novel phenylpyrazinones as kinase inhibitors
JP5318952B2 (ja) 2008-07-15 2013-10-16 エフ．ホフマン−ラ ロシュ アーゲー 新規なフェニル−イミダゾピリジン類及びピリダジン類
WO2010009342A2 (en) 2008-07-16 2010-01-21 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors
CA2725512C (en) 2008-07-18 2016-06-28 F. Hoffmann-La Roche Ag Novel phenylimidazopyrazines
JP2011529073A (ja) 2008-07-24 2011-12-01 ブリストル−マイヤーズ スクイブ カンパニー キナーゼ調節因子として有用な縮合ヘテロ環化合物
CN102405284B (zh) 2008-09-05 2016-01-20 新基阿维罗米克斯研究公司 设计不可逆抑制剂的算法
AU2009308675A1 (en) 2008-10-31 2010-05-06 Genentech, Inc. Pyrazolopyrimidine JAK inhibitor compounds and methods
US20120028981A1 (en) 2008-11-05 2012-02-02 Principia Biopharma Inc. Kinase Knockdown Via Electrophilically Enhanced Inhibitors
EP2365970B1 (en) 2008-11-12 2018-03-21 Gilead Connecticut, Inc. Pyridazinones and their use as btk inhibitors
US8426428B2 (en) 2008-12-05 2013-04-23 Principia Biopharma, Inc. EGFR kinase knockdown via electrophilically enhanced inhibitors
WO2010068788A1 (en) 2008-12-10 2010-06-17 Cgi Pharmaceuticals, Inc. Heterocyclic amides as btk inhibitors
WO2010068806A1 (en) 2008-12-10 2010-06-17 Cgi Pharmaceuticals, Inc. Amide derivatives as btk inhibitors in the treatment of allergic, autoimmune and inflammatory disorders as well as cancer
WO2010068810A2 (en) 2008-12-10 2010-06-17 Cgi Pharmaceuticals, Inc. Certain substituted amides, method of making, and method of use thereof
PE20110819A1 (es) 2008-12-19 2011-11-02 Bristol Myers Squibb Co Compuestos de carbazol carboxamida utiles como inhibidores de cinasa
CA2748181C (en) 2009-01-06 2019-07-16 Nathanael S. Gray Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders
US8299077B2 (en) 2009-03-02 2012-10-30 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase
CN102292329B (zh) 2009-04-24 2014-09-03 霍夫曼-拉罗奇有限公司 布鲁顿酪氨酸激酶的抑制剂
US8765754B2 (en) 2009-04-29 2014-07-01 Locus Pharmaceuticals, Inc. Pyrrolotriazine compounds
WO2010144647A1 (en) 2009-06-12 2010-12-16 Bristol-Myers Squibb Company Nicotinamide compounds useful as kinase modulators
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
EP2464647B1 (en) 2009-08-11 2016-09-21 Bristol-Myers Squibb Company Azaindazoles as btk kinase modulators and use thereof
TWI711610B (zh) 2009-09-04 2020-12-01 美商百健Ｍａ公司 布魯頓氏酪胺酸激酶抑制劑
US9029359B2 (en) 2009-09-04 2015-05-12 Biogen Idec Ma, Inc. Heteroaryl Btk inhibitors
US7741330B1 (en) * 2009-10-12 2010-06-22 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase
BR112012028530A2 (pt) 2010-05-07 2017-12-19 Genentech Inc composto, composição farmacêutica e seu processo de preparação e método para o tratamento de uma doença ou transtorno
EP3112368B1 (en) 2010-05-31 2020-02-12 Ono Pharmaceutical Co., Ltd. Purinone derivative as btk kinase inhibitor
NZ753024A (en) 2010-06-03 2020-08-28 Pharmacyclics Llc The use of inhibitors of bruton’s tyrosine kinase (btk)
US8685969B2 (en) 2010-06-16 2014-04-01 Bristol-Myers Squibb Company Carboline carboxamide compounds useful as kinase inhibitors
RU2585177C2 (ru) 2010-06-23 2016-05-27 Ханми Сайенс Ко., Лтд. Новые конденсированные пиримидиновые производные для ингибирования тирозинкиназной активности
US20120053189A1 (en) 2010-06-28 2012-03-01 Pharmacyclics, Inc. Btk inhibitors for the treatment of immune mediated conditions
EP2603081B1 (en) 2010-08-10 2016-10-05 Celgene Avilomics Research, Inc. Besylate salt of a btk inhibitor
AR082590A1 (es) 2010-08-12 2012-12-19 Hoffmann La Roche Inhibidores de la tirosina-quinasa de bruton
ES2561277T3 (es) 2010-09-01 2016-02-25 Gilead Connecticut, Inc. Piridinonas/pirazinonas, procedimiento de preparación y procedimiento de utilización de las mismas
ES2537190T3 (es) 2010-09-01 2015-06-03 Gilead Connecticut, Inc. Piridazinonas, procedimiento de preparación y procedimientos de utilización de las mismas
WO2012135801A1 (en) 2011-04-01 2012-10-04 University Of Utah Research Foundation Substituted n-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase btk inhibitors
CA2760174A1 (en) 2011-12-01 2013-06-01 Pharmascience Inc. Protein kinase inhibitors and uses thereof
WO2012143522A1 (en) 2011-04-20 2012-10-26 Glaxo Group Limited Tetrahydropyrazolo [1,5 -a] pyrimidine as anti -tuberculosis compounds
US9376438B2 (en) 2011-05-17 2016-06-28 Principia Biopharma, Inc. Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
US20140107151A1 (en) 2011-05-17 2014-04-17 Principia Biophama Inc. Tyrosine kinase inhibitors
BR112013028846B1 (pt) 2011-05-17 2021-12-07 Principia Biopharma Inc Composto ou sal farmaceuticamente aceitável do mesmo, respectivos usos, processo de preparação, intermediários e composição farmacêutica
WO2012156334A1 (en) 2011-05-17 2012-11-22 F. Hoffmann-La Roche Ag Inhibitors of bruton's tyrosine kinase
US9073947B2 (en) 2011-06-10 2015-07-07 Merck Patent Gmbh Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity
WO2013008095A1 (en) 2011-07-08 2013-01-17 Novartis Ag Novel pyrrolo pyrimidine derivatives
ES2927567T3 (es) 2013-09-13 2022-11-08 Beigene Switzerland Gmbh Anticuerpos anti-PD1 y su uso como productos terapéuticos y de diagnóstico
TWI617309B (zh) 2013-10-25 2018-03-11 製藥公司 使用布魯頓氏酪胺酸激酶抑制劑之治療及免疫療法
CN110156892B (zh) 2014-07-03 2023-05-16 百济神州有限公司 抗pd-l1抗体及其作为治疗剂及诊断剂的用途
TW201607930A (zh) * 2014-07-18 2016-03-01 百濟神州有限公司 作為ｔ７９０ｍ／ｗｔ－ｅｇｆｒ的選擇性和不可逆的激酶抑制劑的５－氨基－４－氨甲醯基－吡唑化合物及其用途
PT3179992T (pt) 2014-08-11 2022-07-12 Acerta Pharma Bv Combinações terapêuticas de um inibidor de btk, um inibidor de pd-1 e/ou um inibidor de pd-l1
EP3180343A1 (en) 2014-08-14 2017-06-21 Assia Chemical Industries Ltd. Solid state forms of ibrutinib
WO2016087994A1 (en) 2014-12-05 2016-06-09 Acerta Pharma B.V. Btk inhibitors to treat solid tumors through modulation of the tumor microenvironment
MX381283B (es) 2014-12-18 2025-03-12 Principia Biopharma Inc Tratamiento de pénfigo.
US20180193274A1 (en) * 2014-12-24 2018-07-12 Principia Biopharma Inc. Compositions for ileo-jejunal drug delivery
US9717745B2 (en) 2015-03-19 2017-08-01 Zhejiang DTRM Biopharma Co. Ltd. Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases
WO2017046746A1 (en) 2015-09-15 2017-03-23 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor and a gitr binding molecule, a 4-1bb agonist, or an ox40 agonist
JP2018530550A (ja) 2015-10-01 2018-10-18 ギリアド サイエンシズ， インコーポレイテッド 癌を治療するためのｂｔｋ阻害剤とチェックポイント阻害剤との組合せ
WO2017140254A1 (zh) 2016-02-19 2017-08-24 江苏恒瑞医药股份有限公司 一种含有jak激酶抑制剂或其可药用盐的药物组合物
SG11201901141WA (en) 2016-08-16 2019-03-28 Beigene Ltd Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
CA3034326A1 (en) 2016-08-19 2018-02-22 Beigene, Ltd. Use of a combination comprising a btk inhibitor for treating cancers
EP3545957A4 (en) 2016-11-25 2020-07-22 Jiangsu Hengrui Medicine Co., Ltd. PHARMACEUTICAL COMPOSITION OF PYRIDONE DERIVATIVES AND PROCESS FOR PREPARATION
WO2018137681A1 (en) 2017-01-25 2018-08-02 Beigene, Ltd. Crystalline forms of (s) -7- (1- (but-2-ynoyl) piperidin-4-yl) -2- (4-phenoxyphenyl) -4, 5, 6, 7-tetrahy dropyrazolo [1, 5-a] pyrimidine-3-carboxamide, preparation, and uses thereof
WO2018193105A1 (en) 2017-04-20 2018-10-25 Adc Therapeutics Sa Combination therapy
KR102757960B1 (ko) 2017-06-26 2025-01-22 베이진 엘티디 간세포암(hepatocellular carcinoma: HCC)에 대한 면역 치료
US11377449B2 (en) 2017-08-12 2022-07-05 Beigene, Ltd. BTK inhibitors with improved dual selectivity
WO2019108795A1 (en) 2017-11-29 2019-06-06 Beigene Switzerland Gmbh Treatment of indolent or aggressive b-cell lymphomas using a combination comprising btk inhibitors
MX2020009773A (es) 2018-03-21 2020-10-08 Mei Pharma Inc Terapia de combinacion.
TWI856111B (zh) 2019-06-10 2024-09-21 瑞士商百濟神州瑞士有限責任公司 一種含有布魯頓氏酪胺酸激酶抑制劑的口服固體錠劑及其製備方法
JP2022538215A (ja) 2019-06-10 2022-09-01 ベイジーン スウィッツァーランド ゲーエムベーハー 経口カプセルおよびその調製方法
WO2021018018A1 (en) 2019-07-26 2021-02-04 Beigene, Ltd. Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inidbitors with e3 ligase ligand and methods of use
JP2022548212A (ja) 2019-09-11 2022-11-17 ベイジーン リミテッド マルチチロシンキナーゼ阻害剤及び免疫チェックポイント阻害剤を含む組合せを用いた癌の治療
EP4061851A4 (en) 2019-11-21 2023-12-20 BeiGene, Ltd. METHOD FOR CANCER TREATMENT USING ANTI-OX40 ANTIBODIES IN COMBINATION WITH PI3-KINASE DELTA INHIBITORS
US20230089557A1 (en) 2020-02-27 2023-03-23 Beigene Switzerland Gmbh Methods of treating dlbcl using btk inhibitors and combinations thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014173289A1 (en) * 2013-04-25 2014-10-30 Beigene, Ltd. Fused heterocyclic compounds as protein kinase inhibitors

Also Published As

Publication number Publication date
AU2022200278B2 (en) 2023-10-12
TWI884890B (zh) 2025-05-21
JP7637459B2 (ja) 2025-02-28
KR102793825B1 (ko) 2025-04-11
EP3500575A4 (en) 2020-04-08
EP4353322A3 (en) 2024-07-31
US11814389B2 (en) 2023-11-14
US20240116940A1 (en) 2024-04-11
US11970500B1 (en) 2024-04-30
NZ751418A (en) 2023-04-28
JP7402685B2 (ja) 2023-12-21
IL264784B (en) 2022-07-01
AU2017314178A1 (en) 2019-04-04
US20190169201A1 (en) 2019-06-06
US20240092786A1 (en) 2024-03-21
JP2019528276A (ja) 2019-10-10
US12103931B2 (en) 2024-10-01
AU2024200030A1 (en) 2024-01-25
KR20230162137A (ko) 2023-11-28
CN109563099B (zh) 2023-02-03
US11999743B2 (en) 2024-06-04
TW202511264A (zh) 2025-03-16
JP2024026550A (ja) 2024-02-28
EP4509183A2 (en) 2025-02-19
US11884674B2 (en) 2024-01-30
EP4353322A2 (en) 2024-04-17
US20220274994A1 (en) 2022-09-01
KR20250052473A (ko) 2025-04-18
CN116478165A (zh) 2023-07-25
US20220340583A1 (en) 2022-10-27
US20240059699A1 (en) 2024-02-22
JP7413419B2 (ja) 2024-01-15
ZA201900919B (en) 2020-10-28
IL264784A (enExample) 2019-03-31
US11851437B2 (en) 2023-12-26
EA201990519A1 (ru) 2019-08-30
TW201811794A (zh) 2018-04-01
EP3500575A2 (en) 2019-06-26
CN116478166A (zh) 2023-07-25
US20210130363A1 (en) 2021-05-06
BR112019003205A8 (pt) 2023-01-17
EP4509183A3 (en) 2025-05-21
TW202233628A (zh) 2022-09-01
IL293319A (en) 2022-07-01
CN109563099A (zh) 2019-04-02
WO2018033853A2 (en) 2018-02-22
JP2022071072A (ja) 2022-05-13
JP2025081429A (ja) 2025-05-27
SG11201901141WA (en) 2019-03-28
US20220281881A1 (en) 2022-09-08
US20230057716A1 (en) 2023-02-23
KR102604975B1 (ko) 2023-11-24
TWI760356B (zh) 2022-04-11
KR20190032613A (ko) 2019-03-27
NZ791292A (en) 2025-05-02
US20220340584A1 (en) 2022-10-27
BR112019003205A2 (pt) 2019-06-18
CA3033827A1 (en) 2018-02-22
MX2019001900A (es) 2019-07-01
US10927117B2 (en) 2021-02-23
US20240409546A1 (en) 2024-12-12
WO2018033853A3 (en) 2018-11-01
MX384627B (es) 2025-03-14
EP3500575B1 (en) 2025-11-05
US20230242542A1 (en) 2023-08-03
AU2022200278A1 (en) 2022-02-10
TWI865873B (zh) 2024-12-11
US11591340B2 (en) 2023-02-28

Similar Documents

Publication Publication Date Title
AU2022200278B2 (en) Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hy dropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
HK40109095A (en) Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide,preparation, and uses thereof
EA047328B1 (ru) КРИСТАЛЛИЧЕСКАЯ ФОРМА (S)-7-(1-АКРИЛОИЛПИПЕРИДИН-4-ИЛ)-2-(4-ФЕНОКСИФЕНИЛ)-4,5,6,7-ТЕТРАГИДРОПИРАЗОЛО[1,5-a]ПИРИМИДИН-3-КАРБОКСАМИДА, ЕЕ ПОЛУЧЕНИЕ И ПРИМЕНЕНИЯ

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: BEIGENE SWITZERLAND GMBH

Free format text: FORMER OWNER(S): BEIGENE, LTD.

HB Alteration of name in register

Owner name: BEONE MEDICINES I GMBH

Free format text: FORMER NAME(S): BEIGENE SWITZERLAND GMBH